MedTrace Logo

Dapsone for Acute Ischemia Stroke Study

NCT01144650 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2010-06-15

No results posted yet for this study

Summary

The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.

Conditions

  • Cerebral Stroke
  • Cerebrovascular Accident, Acute
  • Cerebrovascular Stroke
  • Stroke, Acute
  • Stroke

Interventions

DRUG

Dapsone

Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage

DRUG

Placebo

Patients will receive either a single total dose of 250 mg placebo IV and oral dosage

Sponsors & Collaborators

  • El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

    collaborator OTHER

  • Cidat, S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Juan A. Nader, MD · Hospital Medica Sur

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-08-31
Completion
2010-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144650 on ClinicalTrials.gov